Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic LeukemiaAndrew W. Roberts, John F. Seymour, Shekman Wong et al.|New England Journal of Medicine|2015Cited by 1.9k
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin LymphomaMatthew S. Davids, John F. Gerecitano, Andrew W. Roberts et al.|Journal of Clinical Oncology|2017Cited by 752
A Phase 1 Study of Venetoclax (ABT-199 / GDC-0199) Monotherapy in Patients with Relapsed/Refractory Non-Hodgkin LymphomaJohn F. Gerecitano, Matthew S. Davids, Andrew W. Roberts et al.|Blood|2015Cited by 74
ABT-199 (GDC-0199) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): High complete- response rate and durable disease control.John F. Seymour, Andrew W. Roberts, Matthew S. Davids et al.|Journal of Clinical Oncology|2014Cited by 56
Safety, efficacy and immune effects of venetoclax 400 mg daily in patients with relapsed chronic lymphocytic leukemia (CLL).Matthew S. Davids, William G. Wierda, Andrew W. Roberts et al.|Journal of Clinical Oncology|2016Cited by 13